Integra LifeSciences (NASDAQ:IART) Shares Up 8.4% – Time to Buy?

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s stock price shot up 8.4% on Monday . The company traded as high as $17.89 and last traded at $18.0450. Approximately 61,001 shares traded hands during mid-day trading, a decline of 93% from the average session volume of 907,707 shares. The stock had previously closed at $16.65.

Analyst Ratings Changes

Several research analysts have issued reports on IART shares. Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a report on Thursday, June 18th. BMO Capital Markets initiated coverage on shares of Integra LifeSciences in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price target for the company. Truist Financial increased their price objective on shares of Integra LifeSciences from $14.00 to $19.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. Wells Fargo & Company lifted their price objective on shares of Integra LifeSciences from $15.00 to $18.00 and gave the company an “equal weight” rating in a report on Thursday. Finally, Citigroup reissued a “neutral” rating and issued a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $18.86.

Integra LifeSciences Stock Performance

The business has a 50-day moving average of $17.70 and a two-hundred day moving average of $13.47. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.60 and a quick ratio of 2.11. The company has a market cap of $1.39 billion, a P/E ratio of -198.87, a P/E/G ratio of 1.40 and a beta of 1.22.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.08. The business had revenue of $418.76 million during the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, sell-side analysts predict that Integra LifeSciences Holdings Corporation will post 2.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

A number of hedge funds and other institutional investors have recently bought and sold shares of IART. Glenmede Trust Co. NA lifted its position in Integra LifeSciences by 27.4% during the first quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock valued at $9,276,000 after acquiring an additional 211,774 shares during the last quarter. Access Investment Management LLC increased its position in shares of Integra LifeSciences by 72.0% during the first quarter. Access Investment Management LLC now owns 640,535 shares of the life sciences company’s stock worth $6,034,000 after purchasing an additional 268,085 shares in the last quarter. Bank of America Corp DE increased its position in shares of Integra LifeSciences by 71.4% during the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock worth $13,325,000 after purchasing an additional 589,408 shares in the last quarter. Amundi lifted its holdings in shares of Integra LifeSciences by 80.8% during the 1st quarter. Amundi now owns 19,430 shares of the life sciences company’s stock valued at $183,000 after purchasing an additional 8,681 shares during the last quarter. Finally, Maverick Capital Ltd. purchased a new stake in shares of Integra LifeSciences during the 1st quarter valued at $679,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.